Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.

Background: It is unclear whether primary efficacy outcomes in plaque psoriasis clinical trials represent residual disease during treatment.Objectives: To evaluate supplementing dichotomous efficac...